Humacyte, Inc. Files 8-K: Material Agreement and Exhibits
Ticker: HUMAW · Form: 8-K · Filed: Dec 16, 2025 · CIK: 1818382
| Field | Detail |
|---|---|
| Company | Humacyte, Inc. (HUMAW) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $11.50, $60 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, exhibits
Related Tickers: HUMA
TL;DR
Humacyte filed an 8-K on 12/16/25 for a material agreement. Big news pending.
AI Summary
On December 16, 2025, Humacyte, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and exhibits. Humacyte, Inc. is a biotechnology company focused on biological products.
Why It Matters
This 8-K filing signals a significant development for Humacyte, Inc., potentially involving a new material agreement that could impact its operations and financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.
Key Players & Entities
- Humacyte, Inc. (company) — Registrant
- December 16, 2025 (date) — Date of earliest event reported
- Alpha Healthcare Acquisition Corp. (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by Humacyte, Inc. on December 16, 2025?
The filing indicates an 'Entry into a Material Definitive Agreement' as an item information, but the specific details of the agreement are not provided in this excerpt.
What are the key financial statements and exhibits included in this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item information, but the specific contents are not detailed in this excerpt.
When was Humacyte, Inc. formerly known as Alpha Healthcare Acquisition Corp. and when did the name change occur?
Humacyte, Inc. was formerly known as Alpha Healthcare Acquisition Corp., and the date of the name change was July 16, 2020.
What is Humacyte, Inc.'s Standard Industrial Classification (SIC) code and industry?
Humacyte, Inc.'s SIC code is 2836, and its industry is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Where is Humacyte, Inc. headquartered and what is its phone number?
Humacyte, Inc. is headquartered at 2525 East North Carolina Highway 54, Durham, NC 27713, and its business phone number is 919-313-9633.
Filing Stats: 1,201 words · 5 min read · ~4 pages · Grade level 12.3 · Accepted 2025-12-16 17:30:42
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share HUMA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 HUMAW The Nasdaq Stock Market LLC
- $60 — ng an aggregate offering price of up to $60 ,000,000 (the "Shares") during the term
Filing Documents
- tm2533475d2_8k.htm (8-K) — 40KB
- tm2533475d2_ex5-1.htm (EX-5.1) — 11KB
- tm2533475d2_ex10-1.htm (EX-10.1) — 262KB
- tm2533475d2_ex5-1img001.jpg (GRAPHIC) — 19KB
- tm2533475d2_ex5-1img002.jpg (GRAPHIC) — 14KB
- tm2533475d2_ex5-1img003.jpg (GRAPHIC) — 4KB
- 0001104659-25-121674.txt ( ) — 641KB
- huma-20251216.xsd (EX-101.SCH) — 4KB
- huma-20251216_def.xml (EX-101.DEF) — 26KB
- huma-20251216_lab.xml (EX-101.LAB) — 37KB
- huma-20251216_pre.xml (EX-101.PRE) — 25KB
- tm2533475d2_8k_htm.xml (XML) — 6KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement On December 16, 2025, Humacyte, Inc. (the "Company") entered into a Sales Agreement (the "Agreement") with TD Securities (USA) LLC, as agent ("TD Cowen"), under which the Company may offer and sell its common stock, par value $0.0001 per share, from time to time having an aggregate offering price of up to $60 ,000,000 (the "Shares") during the term of the Agreement through TD Cowen, acting as agent. The Company has filed a prospectus supplement relating to the offer and sale of the Shares pursuant to the Agreement. The Shares will be issued pursuant to the Company's previously filed and effective Registration Statement (File No. 333-290231), which was filed with the Securities and Exchange Commission (the "SEC") on September 12, 2025 and was declared effective by the SEC on September 22, 2025. The Company intends to use the net proceeds from the offering, if any, to fund the commercialization of Symvess in the vascular trauma indication, the development of the product candidates in the Company's pipeline and for working capital and general corporate purposes . The Company is not obligated to sell any Shares pursuant to the Agreement. Subject to the terms and conditions of the Agreement, TD Cowen will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of the Nasdaq Global Select Market ("Nasdaq"), to sell Shares from time to time based upon the Company's instructions, including any price, time or size limits or other customary parameters or conditions the Company may impose. Under the Agreement, TD Cowen may sell Shares by any method permitted by law to be an "at the market offering" as defined in Rule 415 of the Securities Act of 1933, as amended (the "Securities Act"), and the rules and regulations thereunder, including, without limitation, sales made directly on or through Nasdaq, on our thro
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 5.1 Opinion of Covington & Burling LLP. 10.1* Sales Agreement, dated as of December 16, 2025, by and between Humacyte, Inc. and TD Securities (USA) LLC. 23.1 Consent of Covington & Burling LLP (contained in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Certain personally identifiable information, marked by brackets, has been omitted from this exhibit pursuant to Item 601(A)(6) of Regulation S-K. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HUMACYTE, INC. Date: December 16, 2025 By: /s/ Dale A. Sander Name: Dale A. Sander Title: Chief Financial Officer, Chief Corporate Development Officer and Treasurer 3